Summer Course for Professionals in “Pharma Law & Policy” at the University of Copenhagen

Stay abreast with recent developments and trends determining the legal and regulatory framework of the European pharmaceutical industry.

What are the most significant current issues shaking and shaping the pharmaceutical industry today? The business environment and legal framework relevant to the pharmaceutical industry continues to change rapidly in the face of constant challenges posed by competition, politics and technological innovation. Considering the highly lucrative and competitive nature of the industry, it is more important than ever for professionals working with legal and regulatory aspects of drug development to stay abreast of the most recent developments.

This course provides a broad and practical understanding of the ‘hot topics’ and will present and analyse these topics from scientific, legal and policy perspectives.

Further information about the course is available here.

Course content

The course begins with a general overview of the current scientific and legal trends in pharmaceutical R&D, organisation and policy. This is followed by a review of the hot topics through a combination of lectures, discussions, group work and case studies. The course is designed to allow room for the issues and challenges crucial to the participants’ daily work and practice.

Participants

The course is designed for professionals working with legal issues and/or regulatory aspects of drug development, decision-makers, administrators and health care practitioners within both the public and private sectors, e.g.:

  • Legal departments in the pharmaceutical industry.
  • Law firms dealing with patent and competition law in the pharmaceutical industry.
  • Branch organizations in the pharmaceutical sector.
  • Health care professionals and decision makers.
  • Bank and finance consultants working with risk and investment in the pharmaceutical industry.

Credit – especially for lawyers and trainee solicitors

This course meets the Danish requirements for compulsory supplementary training for lawyers and trainee solicitors.

Course dates

5 days, 18 – 22 August 2014, 9:00 – 17:00 at the University of Copenhagen, Frederiksberg Campus.

Course director

Timo Minssen, Associate Professor, Dr., LL.M., M.I.C.L., Centre for Information and Innovation Law, Faculty of Law, University of Copenhagen

Other course teachers

Andrew S. Baluch, Special Counsel at Foley & Lardner LLP and former White House Director of International IP Enforcement; Christian K. Schneider, Dr., Medical Head of Division, Medicines Licensing and Availability, Danish Health and Medicines Authority, Chair of EMA’s Biosimilar Working Group and former chair of Committee for Advanced Therapies (CAT). Peter Ganea, Dr., Programme Coordinator of Modern East Asian Studies at Goethe University, Frankfurt; Yan Cai, Vice President IOCMR, Novo Nordisk Region International Operations A/S; Henrik Bendiksen, Senior Patent Councel, Bavarian Nordic GmbH, Martinsried; Sven Frøkjær, Professor, Vice-Dean, Faculty of Health and Medical Science, University of Copenhagen; Rasmus Borup, PhD-student, Section for Social and Clinical Pharmacy, University of Copenhagen; Jacob Bjerg Larsen, Chief Advisor, The Danish Association of the Pharmaceutical Industry (LiF); Jens Schovsbo, Professor, Centre for Information and Innovation Law, University of Copenhagen; Lars Conrad Sparre, European Patent Attorney, Lundbeck A/S; Jesper Thorsen, European Patent Attorney, Inspicos A/S; Jacob Westin, UK based in-house counsel at a major pharma company.

Practical information

Venue: Frederiksberg Campus, Bülowsvej 17, DK-1870 Frederiksberg, Denmark Date: 18-22 August 2014 Registration: on a rolling basis, but May 28th at the latest Fee: EUR 2,600 (DKK 19,000) excl. Danish VAT

T: +45 3532 2870

E: csu@adm.ku.dk

Timo Minssen

Timo Minssen

Timo Minssen is Professor of Law at the University of Copenhagen (UCPH) and the Founder and Managing Director of UCPH's Center for Advanced Studies in Biomedical Innovation Law (CeBIL). He is also affiliated with Lund University as a researcher in Quantum Law. His research concentrates on Intellectual Property, Competition & Regulatory Law with a special focus on new technologies in the pharma, life science & biotech sectors including biologics and biosimilars. His studies comprise a plethora of legal issues emerging in the lifecycle of biotechnological and medical products and processes - from the regulation of research and incentives for innovation to technology transfer and commercialization.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.